Rxivist logo

Analysis of the mechanism of Aldo-keto reductase dependent cis-platin resistance in HepG2 based on transcriptomic and NADH metabolic analysis

By TingtingTingting Sun, Le Gao, Xue Sun, Xin Wang, Rui Guo, Yuanhua Yu

Posted 30 Apr 2021
bioRxiv DOI: 10.1101/2021.04.29.441897

Aldo-keto oxidoreductase (AKR) inhibitors could reverse several cancer cells' resistance to Cis-platin, but their role in resistance remains unclear. Our RNA-seq results showed de novo NAD biosynthesis-related genes, and NAD(P)H-dependent oxidoreductases were significantly upregulated in Cis-platin-resistant HepG2 hepatic cancer cells (HepG2-RC cells) compared with HepG2 cells. Knockdown of AKR1Cs could increase Cis-platin sensitivity in HepG2-RC cells about two-fold. Interestingly, the AKR1C inhibitor meclofenamic acid could increase Cis-platin sensitivity of HepG2-RC cells about eight-fold, indicating that knockdown of AKR1Cs only partially reversed the resistance. Meanwhile, the amount of total NAD and the ratio of NADH/NAD+ were increased in HepG2-RC cells compared with HepG2 cells. The increased NADH could be explained as a directly operating antioxidant to scavenge radicals induced by Cis-platin. We report here that NADH, which is produced by NAD(P)H-dependent oxidoreductases, plays a key role in the AKR-associated Cis-platin resistance of HepG2 hepatic cancer cells.

Download data

  • Downloaded 122 times
  • Download rankings, all-time:
    • Site-wide: 162,603
    • In biophysics: 6,283
  • Year to date:
    • Site-wide: 65,775
  • Since beginning of last month:
    • Site-wide: 58,879

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide